Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid Leukemia
October 30, 2017 08:45 ET
|
Mateon Therapeutics
New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AMLOXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017...
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
September 26, 2017 18:00 ET
|
Mateon Therapeutics
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysisCompany to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia (AML) SOUTH SAN...
Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017
September 06, 2017 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan...
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
August 16, 2017 08:00 ET
|
Mateon Therapeutics
Primary Endpoint - Early Progression Free Survival data favors CA4PCA4P continues to be safe and well-toleratedNext interim analysis expected in September SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 ...
Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 02, 2017 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer
August 01, 2017 07:30 ET
|
Mateon Therapeutics
Recruitment rate significantly increased following initial positive interim analysisInterim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH...
Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
July 31, 2017 07:30 ET
|
Mateon Therapeutics
Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a...
Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors
June 28, 2017 07:30 ET
|
Mateon Therapeutics
CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to controlSurvival benefit observed for...
Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones
June 12, 2017 07:30 ET
|
Mateon Therapeutics
Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017Investigator-Sponsor Pauses Enrollment in PAZOFOS Study in U.K. SOUTH SAN FRANCISCO, Calif., June 12, 2017 (GLOBE...
Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia
June 07, 2017 07:45 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...